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RESEARCH ARTICLE
Inhibition of fibroblast growth factor receptor 3-dependent lung
adenocarcinoma with a human monoclonal antibody
Yongjun Yin1, Xiaodi Ren2, Craig Smith1, Qianxu Guo3, Maria Malabunga4, Ilhem Guernah4, Yiwei Zhang5,
Juqun Shen5, Haijun Sun6,*, Nabil Chehab4,‡, Nick Loizos4, Dale L. Ludwig6 and David M. Ornitz1,§
ABSTRACT
Activating mutations in fibroblast growth factor receptor 3 (FGFR3)
have been identified in multiple types of human cancer and in
congenital birth defects. In human lung cancer, fibroblast growth
factor 9 (FGF9), a high-affinity ligand for FGFR3, is overexpressed in
10% of primary resected non-small cell lung cancer (NSCLC)
specimens. Furthermore, in a mouse model where FGF9 can be
induced in lung epithelial cells, epithelial proliferation and ensuing
tumorigenesis is dependent on FGFR3. To develop new customized
therapies for cancers that are dependent on FGFR3 activation, we
have used this mouse model to evaluate a human monoclonal
antibody (D11) with specificity for the extracellular ligand-binding
domain of FGFR3, that recognizes both human and mouse forms of
the receptor. Here, we show that D11 effectively inhibits signaling
through FGFR3 in vitro, inhibits the growth of FGFR3-dependent
FGF9-induced lung adenocarcinoma in mice, and reduces tumor-
associated morbidity. Given the potency of FGF9 in this mousemodel
and the absolute requirement for signaling through FGFR3, this study
validates the D11 antibody as a potentially useful and effective
reagent for treating human cancers or other pathologies that are
dependent on activation of FGFR3.
KEY WORDS: Lung cancer, NSCLC, Fibroblast growth factor
receptor 3, FGFR3, Adenocarcinoma, Inhibitory monoclonal
antibody
INTRODUCTION
The fibroblast growth factor (FGF) signaling pathway is essential
for organogenesis, tissue homeostasis, repair, and injury-induced
angiogenesis. Aberrant activation of the FGF signaling pathway is
linked to genetic disease and cancer (Dieci et al., 2013; Ellman
et al., 2013; Lemieux and Hadden, 2013; Oladipupo et al., 2014;
Ornitz and Itoh, 2015; Turner and Grose, 2010). The interactions of
FGF receptors (FGFRs) with eighteen signaling FGF ligands
regulates cell proliferation, differentiation, shape, and movement
(Ornitz and Itoh, 2015). The precise cellular response to FGFR
signaling, however, depends on the cell type, developmental stage
and physiologic status of the organism.
Activation of the FGF signaling pathway has been implicated in
animal and human cancers, where it is of considerable interest as a
potential target for therapeutic intervention (Dieci et al., 2013;
Liang et al., 2013; Turner and Grose, 2010). In human lung
adenocarcinoma, whole genome sequencing ranked FGFR3 among
the top 25 significantly mutated genes (Imielinski et al., 2012).
Additionally, increased FGFR3 expression, mutations and gene
fusions were observed in primary human NSCLC, and in cell lines
derived from these tumors (Liao et al., 2013; Majewski et al., 2013);
however, it has not been proven that FGFR3 activation is a driver
event in these cancers. Additionally, increased expression of
FGFR1, FGFR2 and FGFR3 have been implicated in the
acquisition of resistance to activating mutations in the epidermal
growth factor receptor (EGFR) family (Kono et al., 2009; Marek
et al., 2009; Oliveras-Ferraros et al., 2012; Terai et al., 2013; Ware
et al., 2013, 2010). Overexpression, activating mutations and
activating gene fusions in FGFR3 have also been identified in
multiple myeloma, glioblastoma multiforme, bladder, cervical,
gastric, colorectal, head and neck squamous, and germ cell-derived
cancers (Dieci et al., 2013; Ornitz and Itoh, 2015; Turner and Grose,
2010). Mutations in FGFR3 have also been identified as an escape
pathway for inhibitors of B-RAF in melanoma (Yadav et al., 2012).
FGF9 is a potent ligand for FGFR3 (Hecht et al., 1995; Ornitz
et al., 1996). Like FGFR3, FGF9 expression has also been
identified in several tumor types, including breast, prostate,
endometrioid and lung (Hendrix et al., 2006; Li et al., 2008;
Marek et al., 2009; Ohgino et al., 2014), suggesting an important
role in tumorigenesis. Additionally, expression of FGF9 in lung
cancer was associated with poorer prognosis (Ohgino et al., 2014).
To model potential oncogenic roles for FGF9, an inducible
transgenic system was designed to express FGF9 in adult lung
epithelium (White et al., 2006; Yin et al., 2013). Induction of FGF9
expression in adult mice resulted in the rapid conversion of cells in
the bronchioalveolar duct junction into proliferative cells thought to
have progenitor properties that co-express surfactant protein C
(Sftpc), club cell antigen 10 (CC10, Scgb1a1) and Sca-1. Further,
rapidly expanding epithelial tumors could be identified within 24-
48 h of FGF9 induction. Analysis of these tumors indicated a
papillary adenocarcinoma histology and expression of Sftpc, but not
CC10. Moreover, genetic studies showed that the formation of these
tumors was absolutely dependent on FGFR3 (Yin et al., 2013). The
rapid formation of tumors and specificity for FGFR3 indicated that
this model could serve as a highly stringent system to test
therapeutic agents that target FGFR3 or FGF9.
In this study, we characterize a human monoclonal antibody
(D11) that targets the extracellular domain of FGFR3, where it
blocks ligand binding and ligand-induced signaling of both majorReceived 30 January 2016; Accepted 30 March 2016
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splice variants of FGFR3. Using the FGF9-inducible mouse model,
we show that treatment with the D11 monoclonal antibody can be
used to prevent the initiation of tumors and slow the progression of
tumors after induction of FGF9. Furthermore, treatment with D11,
improved tumor-associated weight loss, reduced macrophage
infiltration into lung tissue and reduced cell proliferation in the
bronchioalveolar duct junction.
RESULTS
Characterization of a ligand-blocking anti-FGFR3 human
monoclonal antibody
To further evaluate the role of FGFR3 in tumorigenesis and to
explore the therapeutic potential of targeting this receptor, we
screened a human Fab phage display library and selected an anti-
hFGFR3 fully humanmonoclonal antibody (IMC-D11). D11 bound
to human FGFR3 major splice variants FGFR3b and FGFR3c
extracellular domain-Fc fusion proteins with an EC50 of ∼0.1 nM,
and showed minimal binding to FGFR1, FGFR2, or FGFR4
extracellular domains (Fig. 1A). Additionally, D11 bound to human
and mouse FGFR3b (Fig. 1B) or FGFR3c (Fig. 1C) with similar
affinities. Finally, surface plasmon resonance analysis, a method for
measuring protein interactions (Patching, 2014), indicated that D11
had similar binding affinity to murine, rat, cynomolgus monkey and
human FGFR3b or FGFR3c (data not shown).
To determine whether D11 could recognize FGFR3 splice
variants expressed on the cell surface, we examined antibody
interactions with BaF3 cells that stably express FGFR3b or
FGFR3c. Flow cytometry analysis showed that D11 bound
equally well to BaF3 cells that expressed either the FGFR3b or
FGFR3c splice variants on their cell surface, but not to parental
BaF3 cells that lack FGFR expression (Fig. 1D). Importantly, the
binding of D11 to FGFR3 also blocked the subsequent binding of
FGF1 and FGF9 to both FGFR3b and FGFR3c (Fig. 1E-H) with an
IC50 of ∼1-2 nM. To determine whether the inhibition of ligand
binding was sufficient to inhibit receptor activation, FGFR3-
expressing BaF3 cells were assayed for survival and growth in
response to FGF1 or FGF9 in the presence of increasing
concentrations of D11. Consistent with inhibition of ligand
binding, D11 also effectively inhibited the mitogenic response of
FGFR3-expressing BaF3 cells to FGF1 or FGF9 with an IC50
Fig. 1. D11 binds to FGFR3 receptor and
inhibits ligand binding in vitro. (A) Selective
binding of D11 to FGFR3. Human FGFR1-4 Fc
fusion proteins were immobilized and incubated
with an increasing amount of D11 antibody.
(B,C) Similar binding of D11 to human and mouse
FGFR3b-Fc (B) or FGFR3c-Fc (C) fusion proteins.
(D) Flow cytometry analysis of D11 binding to
FGFR3b- or FGFR3c-expressing BaF3 cells.
(E-H) Inhibition of FGF1 (E,F) and FGF9 (G,H)
ligand binding by D11 to immobilized FGFR3b-Fc
(E,G) or FGFR3c-Fc (F,H) fusion proteins. Specific
binding wasmeasured using SULFO-TAG-labeled
FGF ligands in the presence of increasing
amount of D11. A-D, n=2; E-H, n=3. Error bars
represent s.d.
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ranging from 1.6 to 41.3 nM (Fig. 2A-D). D11 had no detectable
agonist activity under tested conditions (data not shown).
We next examined the growth of UMUC-14 cells (Liebert et al.,
1989; Miyake et al., 2007), a bladder carcinoma cell line that
contains the constitutive activating point mutation, FGFR3S249C, in
the presence of increasing concentrations of D11. D11 treatment
significantly inhibited UMUC-14 cell growth in vitro in a dose-
dependent manner compared with human IgG control (Fig. 2E).
Importantly, D11 also caused FGFR3 receptor loss, possibly
through internalization and degradation, in a dose-dependent
manner in UMUC-14 cells (Fig. 2F,G). FGFR3 receptor loss
mediated by D11 was also observed on multiple myeloma cell
lines, OPM-2 and KMS-11 (data not shown). Thus, D11 was able
to inhibit FGFR3 pathway-dependent cell proliferation through
blocking ligand binding to receptors, and possibly downregulating
cell surface receptors by antibody-induced receptor internalization
and degradation.
D11 inhibits FGF9-dependent lung adenocarcinoma
To determine whether the D11 antibody can inhibit signaling
through FGFR3 in vivo, we employed a mouse model in which lung
epithelial hyperplasia and adenomatous tumor formation is
dependent on FGFR3 (Arai et al., 2015; Yin et al., 2013). The
surfactant protein C–reverse tetracycline activator (Sftpc-rtTA)
transgenic allele was used to activate the doxycycline (Dox)-
responsive Tre-Fgf9-Ires-eGfp transgene (Tichelaar et al., 2000;
White et al., 2006; Yin et al., 2013). In the absence of doxycycline,
adult Sftpc-rtTA, Tre-Fgf9-Ires-eGfp double transgenic mice did not
express GFP and their lungs were histologically normal (Fig. 3B). In
response to doxycycline (provided in chow), Fgf9 and eGFP
expression were robustly induced (Fig. 3C). Within one day
following doxycycline administration, small eGFP-positive nodules
became visible on the lung surface. After four days of doxycycline
induction, the lungs fluoresced green under UV illumination. Lung
histology showed epithelial nodules with a papillary adenoma-like
architecture. The receptor responsible for transducing the FGF9
signal has previously been identified as FGFR3 because induction
of FGF9 on an Fgfr3−/− background did not cause epithelial
hyperplasia, tumors, or an increase in epithelial proliferation (Yin
et al., 2013).
To evaluate the ability of D11 to functionally block the FGFR3
response to induced FGF9, two experimental conditions were
Fig. 2. D11 inhibits proliferation of FGFR3-
expressing cells. (A-D) D11 blocks ligand-
dependent viability of FGFR3b- or FGFR3c-
expressing BaF3 cells. Cells were cultured in
growth medium without FGFs (no ligand), with
3.7 nM FGF1 or FGF9 and 15 µg/ml heparin, alone,
or in combination with control antibody (hIgG) or
D11. Cell viability was measured with CellTiter-Glo
after 72 h incubation with antibodies. (E) D11
inhibits proliferation of bladder cancer cell line
UMUC-14 harboring the FGFR3 S249C mutation.
UMUC-14 cells were incubated with increasing
amount of control antibody (hIgG) or D11 for 72 h.
Cell viability was measured by CellTiter-Glo. (F,G)
Western blot showing incubation with D11 causes
FGFR3 protein loss. UMUC-14 cell lysates after
72 h incubation with control antibody (hIgG) or
increasing amounts of D11 were analyzed by SDS-
PAGE and probed with anti-FGFR3 and anti-tubulin
antibodies (F). Bands were detected and quantified
using a Fujifilm LAS-4000 Luminescence Image
Analyzer (G). A-D, n=3; E-G, n=2. Error bars
represent s.d.
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tested. In the lower stringency condition, the D11 antibody was
injected intraperitoneally into Sftpc-rtTA, Tre-Fgf9-Ires-eGfp mice
(40 mg/kg) beginning two days prior to induction of FGF9 with
doxycycline (Fig. 3A). In the higher stringency condition, the D11
antibody was injected into Sftpc-rtTA, Tre-Fgf9-Ires-eGfp mice
beginning two days after induction of FGF9 with doxycycline
(Fig. 4A). In both cases, mice were maintained on doxycycline
chow for an additional 14 days and the D11 antibody was repeatedly
injected every two days. On day 17 of the experiment (24 h after the
last antibody injection), mice were weighed and then euthanized.
Plasma was collected to assay for circulating antibody levels and
lungs were evaluated for green fluorescence and histopathology.
Control Sftpc-rtTA, Tre-Fgf9-Ires-eGfpmice that were not placed
on doxycycline chow showed no eGFP fluorescence, and had
normal lung histology (Fig. 3B) consistent with the previously
observed very low background expression of the Tre-Fgf9-Ires-
eGfp transgene. Sftpc-rtTA, Tre-Fgf9-Ires-eGfp mice that were
Fig. 3. D11 antibody prevents tumor growth in lungs induced to express
FGF9. (A) Experimental scheme for low-stringency conditions, in which mice
received two D11 antibody injections (arrows) 48 h and 6 h prior to induction of
FGF9 with doxycycline chow (solid line). D11 injections and doxycycline
induction continued for an additional 14 days. Mice were euthanized 24 h after
the last antibody injection. (B-D) Representative images of whole lungs,
corresponding eGFP fluorescence, and histology, from Sftpc-rtTA, Tre-Fgf9-
Ires-eGfp mice. (B) Uninduced control mice; (C) control mice induced with
doxycycline for 14 days (1 of 9 shown); (D) experimental mice induced with
doxycycline for 14 days and injected with D11 antibody (3 of 14 shown).
(E) Body weight change of doxycycline-induced control (n=9) and D11
antibody-treated (n=14) mice showing reducedweight loss in D11-treatedmice
(P<0.0001). (F) Pathology score of doxycycline-induced control (n=9) and D11
antibody-treated (n=14) mice showing improved lung histology in D11
antibody-treated mice (P<0.0001). Scale bars: B-D whole lungs and eGFP
panels, 2.0 mm; histology panels, 200 µm.
Fig. 4. D11 antibody inhibits tumor growth after induction of FGF9.
(A) Experimental scheme for higher stringency conditions, in which mice were
induced with doxycycline chow two days before receiving the D11 antibody
injection (arrows). Doxycycline induction and D11 injections continued for an
additional 14 days. Mice were euthanized 24 h after the last antibody injection.
(B-C) Representative images of whole lungs, corresponding eGFP
fluorescence and histology, from Sftpc-rtTA, Tre-Fgf9-Ires-eGfp mice.
(B) Control mice induced with doxycycline for 17 days (1 of 4 shown);
(C) experimental mice induced with doxycycline for 12 days and injected with
D11 antibody (5 of 10 shown). (D) Body weight change of doxycycline-induced
control (n=4) and D11 antibody-treated (n=10) mice showing reduced weight
loss in D11-treated animals (P<0.0002). (E) Pathology score of doxycycline-
induced control (n=4) and D11 antibody-treated (n=10) mice showing
improved lung histology in antibody-treated mice (P<0.008). Scale bars: B-C
whole lungs and eGFP panels, 2.0 mm; histology panels, 200 µm.
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given doxycycline chow for 16 days and not injected with antibody
or injected with saline showed brightly fluorescent lungs with large
bright green nodules (Fig. 3C). These mice showed a significant
weight loss [−3.2±0.3 g (mean±s.d.), n=9] over the 17-day
experiment. Lung histology showed large tumor nodules, in some
cases occupying nearly an entire lobe. In contrast, Sftpc-rtTA, Tre-
Fgf9-Ires-eGfp mice pre-treated with D11 antibody and injected
every two days thereafter, showed improved lung histology
(Fig. 3D). Importantly, these mice gained weight (0.5±0.5 g,
n=14) over the experimental period (Fig. 3E). Plasma levels of D11
antibody were not detectable in uninjected or saline-injected mice.
In D11-injected mice, the mean plasma levels, measured 24 h after
the last injection, were 1124 µg/ml (range 660 to 1620 µg/ml).
To semi-quantitatively evaluate the efficacy of D11 treatment, we
developed a pathology scoring system (see materials and methods
and Fig. S1). In this system, a score of 0 represents normal lung and
a score of 5 represents lung tissue that is filled with tumor (no
normal lung). Sftpc-rtTA, Tre-Fgf9-Ires-eGfp mice that were
induced with doxycycline and injected with saline showed an
average pathology score of 3.8±0.1, n=9 (Fig. 3F). In contrast, mice
that were treated with D11 antibody showed a significantly reduced
average pathology score of 1.8±0.2, n=14 (P<0.0001 compared
with controls).
The efficacy of D11 antibody treatment was next evaluated using
a more stringent protocol, in which Sftpc-rtTA, Tre-Fgf9-Ires-eGfp
mice were induced with doxycycline for two days before beginning
antibody injections. After two days of doxycycline induction Sftpc-
rtTA, Tre-Fgf9-Ires-eGfp mice showed small epithelial tumor
nodules and widespread epithelial hyperplasia (Fig. S2). After a
total of 17 days induction with doxycycline, control mice developed
widespread adenomatous tumors (Fig. 4B) and lost significant
weight (−6.3±1.1 g, n=4) (Fig. 4D). These mice had a mean
pathology score of 3.9±0.1, n=4. In contrast, mice treated with D11
antibody showed improved histology (Fig. 4C), average weight gain
of 0.4±0.6 g, n=10 (P<0.0001 compared with controls) (Fig. 4D),
and a significantly lower average pathology score of 2.3±0.3, n=10
(P<0.008 compared with controls) (Fig. 4E). In D11-injected mice,
the plasma levels of D11 antibody, measured 24 h after the last
injection, were 1271 µg/ml (range 937 to 1665 µg/ml).
A third experiment was performed to examine tumor regression.
Previous studies demonstrated that after doxycycline induction for
up to two weeks, followed by doxycycline withdrawal for up to
18 weeks, the established tumor mass remained stable and became
independent of FGF9–FGFR3 signaling (Arai et al., 2015; Yin
et al., 2013). To determine whether treatment with the D11 antibody
could cause tumor regression, we induced Sftpc-rtTA, Tre-Fgf9-
Ires-eGfpmicewith doxycycline for 7 days. Doxycycline chowwas
then replaced with normal chow and D11 antibody was injected
every 2 days for 14 days. Pathology scores of control mice not
injected with D11 antibody, or experimental mice injected with D11
antibody, were not different (mean pathology score: without
antibody 2.5±1.4, with antibody injection 2.5±1.4), indicating that
once tumors were established, inhibition of FGFR3 was not
sufficient to accelerate tumor regression of these FGF9–FGFR3-
independent tumors (data not shown).
D11 inhibits the proliferation of Sftpc+/CC10+
bronchioalveolar duct junction cells
Previous studies using the Sftpc-rtTA, Tre-Fgf9-Ires-eGfp mouse
model demonstrated that short-term (16 h) induction with
doxycycline resulted in increased proliferation of Sftpc+/CC10+
cells within 25 cells of the bronchioalveolar duct junction (BADJ)
(Yin et al., 2013). To determine whether D11 antibody treatment
could affect proliferation or the number of Sftpc+/CC10+ cells in the
bronchioalveolar duct junction region, Sftpc-rtTA, Tre-Fgf9-Ires-
eGfp mice were injected with two doses of D11 antibody 24 h and
9 h before being placed on doxycycline chow for 16 h (Fig. 5A).
After 16 h of induction, control Sftpc-rtTA, Tre-Fgf9-Ires-eGfp
mice showed conversion of nearly all epithelial cells in the BADJ
region to Sftpc+/CC10+ cells, and nearly all of these cells were
positive for PCNA (Fig. 5B-E,J,K). Treatment with the D11
antibody did not affect the increase in BADJ region Sftpc+/CC10+
cells in response to induction of FGF9 (Fig. 5F-J). However, D11
antibody treatment was associated with a significant (P<0.002)
decrease in PCNA-positive cells in the BADJ region in these mice
(Fig. 5K).
Decreased infiltration of multinucleated macrophages in
D11-treated mice
Tumor induction in Sftpc-rtTA, Tre-Fgf9-Ires-eGfp mice is often
associated with the infiltration of large multinucleated macrophages
(Fig. 6A,B; Fig. S4) (Arai et al., 2015). Macrophage infiltration is
evident by 24 h of induction and often resolves after several weeks,
Fig. 5. Inhibition of Sftpc+/CC10+ double-positive cell proliferation by the
D11 antibody. (A) Experimental schematic. Arrows indicate D11 injections.
Solid line indicates doxycycline treatment. (B-I) Immunofluorescence showing
Sftpc, CC10 and PCNA expression as indicated in lung bronchioalveolar duct
junction regions from Sftpc-rtTA, Tre-Fgf9-Ires-eGfp mice induced with
doxycycline for 16 h. Control mice (B-E) were not injected and experimental
mice (F-I) received two doses of D11 antibody injections prior to doxycycline
induction. Arrows indicate examples of cells expressing all three markers.
(J) Quantitation of the number of Sftpc+/CC10+ double-positive cells in the
terminal bud region (defined as within 25 cells of the BADJ) (n=3 mice).
(K) Quantitation of the ratio of PCNA-positive cells to Sftpc+/CC10+ double-
positive cells in the terminal bud region (n=3 mice). Data plotted as mean±s.d.,
*P<0.002. Scale bar: 50 µm.
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leaving behind adenomatous tumor nodules. Additionally, in some
tumors (including D11-treated mice), lymphoid nodules or diffuse
lymphocyte infiltration are observed throughout the lung tissue
following doxycycline induction (Fig. 6C,D). The mechanism
leading to immune infiltration is not known, but could result from
direct signaling by FGF9 to immune cells or to inflammatory
cytokine production by developing epithelial tumors.
To determine whether D11 antibody treatment affects immune
cell infiltration we developed an immune score scale to evaluate the
degree of immune cell infiltration (Fig. S3). Interestingly, treatment
with D11 antibody significantly reduced multinucleated
macrophage infiltration (Fig. 6E) but had little effect on
lymphocyte infiltration (Fig. 6F; Fig. S4). This suggests that
multinucleated macrophage infiltration is very sensitive to lung
pathology mediated by signaling through FGFR3 whereas
lymphocyte infiltration might be secondary to signals mediated
by other FGF receptors.
DISCUSSION
The future for treatment of human cancers will require redundant
therapies targeted to tumor-specific pathways and the tumor
microenvironment. Thus, the identification of signaling pathways
required by specific tumor types and the development of therapeutic
agents that effectively target these pathways will be essential
to the next generation of cancer treatments. Mutation, gene
rearrangements and gene amplifications that effectively activate
the FGFR3 tyrosine kinase domain are currently associated with
several human tumors, including adenocarcinoma of the lung,
multiple myeloma, glioblastoma multiforme, nasopharyngeal,
bladder, cervical, gastric, colorectal and germ cell-derived cancers
(Cappellen et al., 1999; Cheng et al., 2013; Chesi et al., 2001; Ewen
et al., 2013; Jang et al., 2001; Kompier et al., 2010; Ornitz and Itoh,
2015; Singh et al., 2012; Turo et al., 2015; Wang et al., 2014;
Williams et al., 2013; Wu et al., 2013). Furthermore, FGF9, a high-
affinity ligand for FGFR3 is expressed in a large percentage of lung,
prostate, and colon cancers (Leushacke et al., 2011; Ohgino et al.,
2014; Teishima et al., 2014).
In a mouse model for adenocarcinoma of the lung, activation of
epithelial-expressed FGFR3 by induced expression of FGF9 results
in rapid changes in the differentiation state of BADJ cells, increased
proliferation of Sftpc+/CC10+ BADJ cells and type II pneumocytes,
and the rapid formation of adenomatous tumor nodules (Yin et al.,
2013). The rapid development of lung pathology and its complete
dependence on signaling through FGFR3makes this model ideal for
testing or screening for drugs that can inhibit the FGFR3 signaling
pathway in vivo, such as a blocking antibody to FGFR3.
D11 is a humanmonoclonal antibody that targets the extracellular
domain of FGFR3. We show that the D11 antibody specifically
recognizes human and mouse FGFR3 and has very low affinity for
other FGFRs. We further show that D11 inhibits a mutant form of
FGFR3 harboring a gain-of-function missense mutation, and
additionally, inhibits ligand-induced activation of FGFR3.
Because D11 also readily cross-reacts with mouse FGFR3, to
demonstrate potential therapeutic efficacy we showed that mice
given serial intraperitoneal injections of D11 over two weeks
attained average plasma levels of >1000 µg/ml and showed normal
weight gain and no apparent adverse effects of treatment. In a short-
term treatment protocol in mice, adverse effects would most likely
result from consequences of on-target inhibition of FGFR3,
possible off-target interference with other physiologically active
molecules, or an acute immune response. The lack of adverse effects
of D11 treatment is consistent with on-target activity against FGFR3
and the knowledge that mice that congenitally lack FGFR3 are
viable (Colvin et al., 1996). These studies further suggest that D11
has minimal off-target interference with other FGFRs or other non-
related proteins.
The Sftpc-rtTA, Tre-Fgf9-Ires-eGfp mouse model is a highly
stringent test for an anti-FGFR3 drug, in that FGF9 is induced
throughout the lung (type II pneumocytes and distal airway
epithelial cells), and the resulting lung pathology has a rapid
onset characterized by acutely increased epithelial proliferation in
distal airways, formation of adenomatous nodules, and
inflammatory infiltration. The observation that D11, even when
administered two days following FGF9 induction, has the ability to
suppress FGFR3-dependent pathology in vivo without adverse side
effects suggests that this antibody has significant therapeutic
potential.
A previously developed monoclonal antibody, R3Mab, directed
towards the FGFR3 extracellular domain (Qing et al., 2009)
effectively blocks ligand binding and ligand-induced activation of
the wild-type receptor and inhibits ligand-independent FGFR3 with
activating missense mutations in the extracellular domain. R3Mab
was also effective in inhibiting multiple myeloma cells containing
the t(4;14)(p16.3;q32) chromosomal translocation that results in the
Fig. 6. Decreased infiltration of multinucleated macrophages in mice
treated with D11 antibody. (A,B) Lung histology from Sftpc-rtTA, Tre-Fgf9-
Ires-eGfp mice induced with doxycycline for 16 days, but not treated with D11
antibody, showing a tumor nodule with dense infiltration of large cells referred
to as multinucleated macrophages. (C,D) Lung histology from Sftpc-rtTA,
Tre-Fgf9-Ires-eGfpmice induced with doxycycline for 16 days and treated with
D11 antibody showing lack of multinucleated macrophage infiltration but
occasional presence of lymphocytic nodules. Boxes in A,C are magnified in B,
D. (E) Semi-quantitative immunoscore for multinucleated macrophages
showing significantly reduced (P<0.0001) infiltration in D11-treated mice
(n=29) comparedwith control (n=16). (F) Immunoscore for lymphocytes shows
no significant difference between D11 antibody-treated (n=32) and untreated
(n=16) mice. Scale bars: A, 100 µm; B, 20 µm.
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expression of an FGFR3–MMSET fusion protein (Chesi et al.,
1998; Qing et al., 2009). Other researchers have demonstrated that a
single-chain anti-FGFR3 Fv fragment fused to a toxin gene product,
rGel, had the ability to inhibit the growth of a xenograft bladder
cancer cell line (Martinez-Torrecuadrada et al., 2008). The D11
antibody also effectively inhibits ligand binding, ligand-induced
receptor activation, and activation of FGFR3 containing an
activating point mutation. Furthermore, D11 causes internalization
and degradation of the FGFR3 protein.
In addition to the use of antibodies to target FGFR3, small-
molecule inhibitors of the FGFR tyrosine kinase domain have
demonstrated efficacy with several xenograft tumor models. For
example, the pan-FGFR selective tyrosine kinase inhibitors,
SU5402 and PD173074, effectively blocked the growth of t(4;14)
(p16.3;q32) multiple myeloma cells (Grand et al., 2004). However,
no small-molecule inhibitors have been identified with specificity
for FGFR3 over other FGFRs. Thus, the use of antibodies,
potentially coupled to toxins or other biologically functional
molecules, has the potential to provide more customized and
disease-specific therapy while minimizing adverse side effects.
In addition to the role of activating FGFR3 mutations in a variety
of cancers, germline-activating mutations in FGFR3 are the etiology
of achondroplasia, the most common form of skeletal dwarfism in
humans, and somatic activating mutations in FGFR3 cause
seborrheic keratosis, a benign skin tumor, and epidermal nevi, a
benign hyperplastic skin lesion (Hafner et al., 2006; Logie et al.,
2005; Naski et al., 1996). Activation of the C-type natriuretic
peptide (CNP) signaling pathway, which antagonizes FGFR3
signaling in chondrocytes, is being evaluated as a therapeutic for
achondroplasia (Lorget et al., 2012). Antibodies that effectively
inhibit FGFR3 activity in vivowould also be potential candidates to
treat skeletal dwarfism and other pathologies associated with
achondroplasia. Synergism with other activators of chondrocyte
proliferation, such as CNP, might provide a more effective treatment
with fewer side effects. This is important, given that treatment of
achondroplasia will be required throughout much of the prepubertal
growth years of affected children.
MATERIALS AND METHODS
Identification of a human anti-FGFR3 antibody from a phage
display library
A human Fab phage display library was panned (Eli Lilly and Company,
New York, NY) for anti-FGFR3IIIc antibodies using human FGFR3IIIc-Fc
(R&D Systems, Minneapolis, MN; #766-FR-050) as the bait. Individual
phage clones recovered after the second and third rounds of selections were
examined for binding to immobilized hFGFR3IIIc/Fc and for blocking
hFGFR3/FGF2 interaction by ELISA. The DNA sequences encoding the
heavy-and light-chain variable genes for the selected antibody, IMC-D11
(D11; Eli Lilly and Company), were amplified by PCR and cloned into an
expression vector containing human λ light-chain constant region and
human γ1 heavy-chain constant region. D11 monoclonal antibody was
produced from individual clones of stably transfected CHO cells.
ELISA binding and MSD blocking assays
Various amounts of phage, Fab, or monoclonal antibody were serially
diluted in 0.2% Tween 20/PBS containing 1% BSA, and added to
hFGFR3IIIc-coated plates (50 µl at 1 µg/ml) and incubated at room
temperature for 2 h. The bound antibodies were detected with an anti-
human Fab antibody conjugated with HRP (Jackson ImmunoResearch,
West Grove, PA; #109-035-097) in binding assays, or continuously probed
with SULFO-TAG-labeled FGFs (Meso Scale Discovery, Rockville, MD;
# R91AN-1) in blocking assays according to the supplier’s instructions.
250 nM NaCl was present in ELISA binding and washing steps, and
10 µg/ml heparin was present in ligand-blocking assays. Human FGF1
(Genway Biotech Inc., San Diego, CA; #GWB-54AEB0), Human FGF9
(R&D Systems; #273-F9).
Cell lines and proliferation assays
Murine pro-B cell line BaF3 parental cells (Mathey-Prevot et al., 1986;
Palacios and Steinmetz, 1985) were maintained in RPMI-1640 (Invitrogen,
Carlsbad, CA) with 10% FBS (heat inactivated, Hyclone, Logan, UT),
5 ng/ml murine IL-3 (R&D Systems); BaF3 cells stably transfected with
FGFR3 were maintained in the above medium supplemented with 2 µg/ml
puromycin (Sigma-Aldrich, St. Louis, MO). Cell lines were confirmed to be
IL3-dependent and puromycin-resistant. No further authentication was
carried out on these cells. For flow cytometry, BaF3 cells were incubated
with 10 µg/ml D11 and 1:200 dilution of secondary anti-hIgG-PE (Jackson
ImmunoResearch: #109-116-088). After washing, cells were analyzed on a
Guava EasyCyte Plus flow cytometry system (Millipore, Billerica, MA). For
IMC-D11-blocking BaF3/FGFR3 cell proliferation assays, 25,000 cells/well
were seeded in 96-well plates. After incubation with serially diluted D11 for
1 h, FGF ligands were added to 3.7 nM final concentration for 72 h. Cell
viability was determined using the CellTiter-Glo Luminescent Cell Viability
Assay (Promega, Madison, WI).
UMUC-14 cells (Liebert et al., 1989), obtained from MD Anderson
Cancer Center, were maintained in DMEM medium (ThermoFisher,
Invitrogen, Grand Island, NY) supplemented with 10% FBS (Hyclone)
under conditions of 5% CO2 at 37°C. The mutation in FGFR3 was
confirmed by PCR amplification and sequencing. No further authentication
was carried out on these cells. For D11-blocking UMUC-14 cell
proliferation assay, cells were incubated with 1:3 serial-diluted D11 from
200 nM and/or 200 nM human IgG control antibody (Equitech-Bio,
Kerrville, TX; #SLH56) for 72 h. Cell viability was determined using the
CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI).
Western blot
Cell lysates (15 µg) from UMUC-14 cells were subjected to SDS-PAGE
followed by western blot. Blots were probed with anti-FGFR3 antibody
(1:2,000; Sigma-Aldrich; #F0425) or anti-tubulin antibody (1:2,000; Cell
SignalingTechnology, Danvers,MA; #2125), and secondaryanti-Rabbit IgG
HRP antibody (1:10,000; Jackson ImmunoResearch; #111-035-144). Bands
were detected and quantified using a Fujifilm LAS-4000 Luminescence
Image Analyzer (GE Healthcare Life Sciences, Pittsburg, PA).
Detecting mouse plasma IMC-D11 antibody
Serially diluted plasma samples or purified D11 antibodies were added to
goat anti-human IgG-coated plates, and detected with an HRP-conjugated
goat anti-human IgG Fc γ-specific antibody (1:10,000; Jackson
ImmunoResearch; #109-035-098).
Mice
The Sftpc-rtTA, Tre-Fgf9-Ires-eGfp mouse strain has been previously
described (Perl et al., 2002; Tichelaar et al., 2000; White et al., 2006; Yin
et al., 2013, 2008). Sftpc-rtTA, Tre-Fgf9-Ires-eGfpmice were maintained on
an inbred FVB genetic background. All micewere housed in a pathogen-free
animal facility under the veterinary care of the Department of Comparative
Medicine at Washington University School of Medicine, and used at the age
of six-to-twelve weeks. All protocols were approved by the Washington
University Animal Studies Committee and were performed in accordance
with the Animal Welfare Act and the Guide for the Care and Use of
Laboratory Animals.
Transgene induction and D11 antibody injection
Doxycycline (Dox) diet was purchased from Bio-Serv Inc. (200 mg/kg
green pellets, #S3888). Mice were fasted for 6 h prior to providing
doxycycline chow at 6 pm on the first day of induction. Doxycycline chow
was provided ad libitum throughout the experiment. The D11 antibody was
diluted with 1× PBS and injected intraperitoneally at a dose of 40 mg/kg
(∼0.5 ml/mouse). Control mice were either not injected or injected with
0.5 ml of 0.9% saline. Body weight was measured before induction and on
the day of necropsy.
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Lung pathology, histology, and immunohistochemistry
Mice were anesthetized with KXA (31 mg/kg ketamine, 6 mg/kg xylazine,
1 mg/kg acepromazine) and transcardially perfused with a vascular rinse of
0.9% NaCl followed by 10% neutral buffered formalin (VWR International;
#89370-094). Lungs were dissected and photographed under bright-light
illumination and under UV light using an Olympus SZX12-ILLD100
dissecting microscope (Olympus Optical Co. Ltd). Tissues were postfixed in
10% phosphate buffered formalin overnight at 4°C. All five lobes were
separated, embedded in paraffin and sectioned using standard procedures.
For histology, slides were stained with hematoxylin and eosin (H&E). For
immunofluorescence staining, sections were rehydrated. Antigen retrieval
was achieved by boiling at 121°C for 15 min in 10 mM citrate buffer
followed by gradual cooling to room temperature. Sections were incubated
overnight at 4°C with the primary antibodies, and after incubation with the
primary antibodies, appropriate Alexa Fluor-coupled secondary antibodies
(Thermo Fisher; #A21206, #A21203, #A21447) were applied at a 1:200
dilution. Sections were photographed on an ApoTome fluorescence
microscope (Zeiss Inc). The following primary antibodies were used for
staining: CC10 (Scgb1a1, sc-9772; Santa Cruz Biotechnology Inc.; 1:200);
pro-SP-C (SftpC, AB3786; Millipore; 1:2000); PCNA (sc-56; Santa Cruz
Biotechnology Inc.; 1:100); CD45 (ab10558; Abcam, Cambridge, MA;
1:200). For the CD45 antibody, immunostaining was detected using the
Histostain-SP Broad Spectrum (DAB) kit (Thermo Fisher; #95-9643).
For quantitation of cell number, multiple optical sections were scored
manually to distinguish cell boundaries and identify the bronchioalveolar
duct junction. Sfptc- and CC10-positive cells were counted within 25 cells
of the bronchioalveolar duct junction as described (Yin et al., 2013). Three
different whole-lung longitudinal sections containing the main axial bronchi
were scored for each mouse.
Pathology and immunology scores
We developed a histopathological scoring system (Fig. S1 and S3) to
provide semi-quantitative analysis of the extent of tumor growth and
inflammatory infiltrates (Gibson-Corley et al., 2013). For lung
tumorigenesis, we based this scoring system in part on the Ashcroft
scoring system, which is commonly used to evaluate the extent of lung
fibrosis (Ashcroft et al., 1988; Guzy et al., 2015).
For each mouse sample, 2-3 H&E slides were selected from different
depths of the tissue, separated by at least 50 µm. Three to five lobes were
viewed for each mouse. Two persons scored the slides and were blind to the
identity of the mouse or the treatment. The pathology score was defined as:
0, normal lung tissue; 1, alveolar or ductal hyperplasia; 2, 1-3 tumor nodules
in at least one lobe; 3, many tumor nodules in multiple lobes; 4, solid tumor
in at least one lobe; 5, solid tumor, no normal lung (Fig. S1).
The immunology score was defined as: 0, no inflammation; 1-L, diffuse
lymphocyte infiltration, no nodules; 2-L, peribrochiolar lymphocyte
clusters, <4 clusters in one lobe with >10 cells per cluster; 3-L,
peribrochiolar lymphocyte clusters, ≥4 clusters in one lobe with >10 cells
per cluster; 1-M, diffuse multinucleated macrophage infiltration; 2-M, dense
multinucleated macrophage infiltration (Fig. S3).
Statistical analysis
All data are expressed as mean±standard derivation (s.d.), Student’s t-test
values indicate statistical significance for comparable tissues, P values were
obtained using GraphPad Prism and Microsoft Excel software.
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